A Phase II Study Of Sunitinib Malate Single Agent For The Treatment Of Women With Advanced Breast Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of Participants With Objective Response
Number of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as disappearance of all target lesions. PR defined as a greater than or equal to 30 percent (≥30%) decrease in sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Baseline, Week 9, and every 8 weeks up to Month 34
No
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
A6181068
NCT00471276
August 2007
June 2010
Name | Location |
---|---|
Pfizer Investigational Site | Blendora, California 91740 |
Pfizer Investigational Site | Crestview Hills, Kentucky 41017 |
Pfizer Investigational Site | Detroit, Michigan 48201 |
Pfizer Investigational Site | Rochester, Minnesota 55905 |
Pfizer Investigational Site | Springfield, Illinois 62701-1014 |
Pfizer Investigational Site | Federal Way, Washington 98003 |
Pfizer Investigational Site | Clearwater, Florida 33761 |
Pfizer Investigational Site | Columbia, Missouri 65201 |
Pfizer Investigational Site | Asheville, North Carolina 28801 |
Pfizer Investigational Site | Bristol, Tennessee 37620 |
Pfizer Investigational Site | Bismarck, North Dakota 58503 |